TRASTUZUMAB VIDETECAN
UNII TX2F9X2RBH

Substance Identification & Data

This profile provides standardized clinical and technical data for Trastuzumab Videtecan, uniquely identified by the FDA Unique Ingredient Identifier (UNII) TX2F9X2RBH.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 3061833-59-5 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code
TX2F9X2RBH
CAS Registry Number
3061833-59-5
RxNorm Concept ID
N/A

Detailed Substance Profile

Preferred Name
TRASTUZUMAB VIDETECAN
Official standardized name for this substance within the FDA UNII nomenclature system.
INN ID
14030
Sequential identifier assigned via the WHO International Nonproprietary Name program.
Substance Type
protein
ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Trastuzumab Videtecan. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

TRASTUZUMAB VIDETECAN

Common Names & Synonyms

IMMUNOGLOBULIN G1, ANTI-(HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2) (HUMAN-MUS MUSCULUS MONOCLONAL BAT0606 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL BAT0606 .KAPPA.-CHAIN, DIMER, REDUCED, THIOETHER WITH (2S)-2-((2-(3-MERCAPTO-2,5-DIOXO-1-PYRROLIDINYL)ACETYL)AMINO)-4-(1-OXO-4,7,10,13,16,19,22,25-OCTAOXAHEXACOS-1-YL)BUTANOYL-L-VALYL-N5-(AMINOCARBONYL)-N-(4-((((((1S,9S)-9-ETHYL-5-FLUORO-2,3,9,10,13,15-HEXAHYDRO-9-HYDROXY-4-METHYL-10,13-DIOXO-1H,12H-BENZO(DE)PYRANO(3',4':6,7)INDOLIZINO(1,2-B)QUINOLIN-1-YL)AMINO)CARBONYL)OXY)METHYL)PHENYL)-L-ORNITHINAMIDE
IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS ERBB2 (RECEPTOR TYROSINE-PROTEIN KINASE ERBB-2, EPIDERMAL GROWTH FACTOR RECEPTOR 2, EGFR2, HER2, HER-2, P185C-ERBB2, NEU, CD340)), HUMANIZED MONOCLONAL ANTIBODY, CONJUGATED ON AN AVERAGE OF EIGHT CYSTEINYL RESIDUES TO VIDETECAN, COMPRISING A LINKER AND A CAMPTOTHECIN DERIVATIVE (EXATECAN) (TRASTUZUMAB VIDETECAN)
TRASTUZUMAB VIDETECAN [INN]

External Clinical & Regulatory Resources

CAS
Common Chemistry
NCATS
Inxight Drugs
NLM
DailyMed Products
NCATS
GSRS Full Record